Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGraft Polymer Regulatory News (GPL)

Share Price Information for Graft Polymer (GPL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.145
Bid: 0.14
Ask: 0.15
Change: 0.00 (0.00%)
Spread: 0.01 (7.143%)
Open: 0.145
High: 0.145
Low: 0.145
Prev. Close: 0.145
GPL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Operational Update

5 Jul 2023 07:00

RNS Number : 9731E
Graft Polymer (UK) PLC
05 July 2023
 

Completion and commissioning of key innovative equipment plant in Slovenia

Strengthening competitive advantage and accelerating growth with doubling of production capacity

A major step forward against backdrop of healthy pipeline, strong 2023 outlook and scope to win larger customer mandates

5 July 2023

Graft Polymer, (LON:GPL) the specialty chemicals company offering modified polymer solutions for refiners, compounders and processors, is today announcing the completion and commissioning of a bespoke production equipment site in Slovenia which is due around the end of July 2023, doubling the company's production capacity.

The company operates in two dynamic sectors with strong growth prospects - the global polymer market, set to grow from US$590 billion in 2021 to US$947 billion by 2030 with a CAGR of 5.4% over this period (source: Prescient & Strategic Intelligence); and the global drug delivery devices market, set to grow from US$78.09 billion in 2021 to US$124.83 billion by 2029, with a CAGR of 5.6% over the period (source: DataM market research, November 2022).

The commissioning of the site is an important development for Graft, as it leverages its IP for bio and pharma applications to expand the breadth of its product ranges and make the company's divisions quicker in responding to customer requirements. It is a key step towards the group realising its growth ambitions centred around expanding its global footprint, competing with well-established peers through its specialist approach focused on innovation and building cashflow generation.

Once operational, the Slovenian plant will effectively double the company's production capacity and heighten its first mover advantage as a market leading, pioneering operator in both research and technology commercialisation within the polymer modification, biological supplement and drug delivery industry. It marks significant progress in the company moving towards being able to satisfy demand for modified polymers for use in creating cutting edge composite materials on an industrial scale.

The company is targeting accelerating growth using its extensive commercial pipeline with production output at the Slovenian plant set to rise to 6,000 tonnes / year. The production process is fully ESG oriented, utilising high levels of recycled material.

Commenting on the development, Victor Bolduev, CEO, said: "The commissioning of this pivotal plant is testament to the group's increasing commercial momentum in a promising market with a continued strong outlook for this year. I am confident that it will play a major role in transforming our ability to win larger customer mandates and strengthen competitive positioning within the speciality chemicals sector, centred on our excellent innovation and specialist production capabilities. Our enlarged scale will also drive greater cashflow generation to the benefit of shareholders".

 

ENDS

 

 

 

For further information, visit www.graftpolymer.com,follow on Twitter @PolymerLtd or contact:

 

Graft Polymer (UK) Plc

Roby Zomer, Non Executive Chairman Via Flagstaff

Yifat Steur, CFO and Executive Chairman

 

Turner Pope Investments Tel:+44 (0) 20 3657 0050

James Pope

Andy Thaker

 

Flagstaff Strategic and Investor Communications Tel + 44 (0) 207 129 1474

Tim Thompson

Mark Edwards

Alison Allfrey

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBRGDRBGGDGXS
12
Date   Source Headline
9th May 20247:00 amRNSUpdate on recent developments
7th May 20247:00 amRNSGrant of Haemostatic Hydrogel Patent
3rd May 20247:00 amRNSDivestment of Graft Polymer d.o.o – Slo facility
2nd May 20247:00 amRNSReplacement of Chief Executive Officer
30th Apr 20245:05 pmRNSAnnual Financial Report
23rd Apr 20244:17 pmRNSLoan facility update
15th Mar 20247:00 amRNSChairman & Directorate Change & Financial Update
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSGM Statement
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSDirector/PDMR Shareholding
27th Dec 20237:00 amRNSGM Notice 8th January 2024
22nd Dec 20237:00 amRNSPlacing of New Ordinary Shares
9th Oct 20237:00 amRNSPivotal Agreement within European Consortium
27th Sep 20237:02 amRNSUpdated Investor Presentation
27th Sep 20237:00 amRNSInterim Financial Results
11th Sep 20237:00 amRNSR&D Agreement with Slovenian Faculty
4th Sep 20237:00 amRNSR&D and supply agreement with FORPET BALTIC
30th Aug 20237:00 amRNSR&D Supply Agreement Signed
23rd Aug 20237:00 amRNSGraft Bio signs manufacturing services agreement
27th Jul 202311:54 amRNSResult of AGM
26th Jul 20237:00 amRNSDistribution agreement with US Inter-Technologies
6th Jul 20237:00 amRNSNew R&D and Supply Agreement with Gabriel Chemie
5th Jul 20237:00 amRNSOperational Update
4th Jul 20237:00 amRNSAGM Notice
16th May 20232:08 pmRNSDirector Share Purchase
27th Apr 20237:00 amRNSFinal Results
21st Mar 20237:00 amRNSGraftBio - MGC Pharma Update
20th Mar 20237:00 amRNSCorporate Presentation
9th Feb 20237:00 amRNSUpdate: New Product Lines & Facility Expansion
30th Sep 20227:00 amRNSInterim Results
20th Sep 20227:00 amRNSNew Corporate Presentation
18th Aug 202210:00 amRNSFirst Commercial Purchase Order for GraftBio
28th Jul 202212:30 pmRNSResult of AGM
4th Jul 20224:50 pmRNSNotice of AGM
29th Jun 20227:00 amRNSFinal Results
20th Jun 20227:00 amRNSOperational Update
17th Jun 20227:00 amRNSGraftBio IP – MGC Pharma Update
18th May 20227:00 amRNSDirector Share Purchase
12th May 20227:00 amRNSHACCP Certificate Enabling Access to B2C Market
22nd Apr 20227:17 amRNSGrant of patents
7th Apr 20227:00 amRNSPre-payment for equipment
6th Apr 202211:50 amRNSDirector/PDMR Shareholding
21st Feb 20227:00 amRNSUpdate on Operations
15th Feb 20227:00 amRNSChange of Year End
25th Jan 20227:00 amRNSBusiness Update
11th Jan 20227:00 amRNSInvestor Presentation
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.